Atossa Therapeutics, Inc. Common Stock
ATOS Real Time Price USDRecent trades of ATOS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Roger Marshall House / R | Purchase $1,001 - $15,000 | Oct. 25, 2017 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ATOS's directors and management
Government lobbying spending instances
-
$40,000 Jan 20, 2016 Issue: Medical/Disease Research/Clinical Labs
-
$40,000 Oct 20, 2015 Issue: Medical/Disease Research/Clinical Labs
-
$10,000 Sep 03, 2015 Issue: Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
New patents grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ATOS in WallStreetBets Daily Discussion
Recent insights relating to ATOS
Recent picks made for ATOS stock on CNBC
ETFs with the largest estimated holdings in ATOS
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ATOS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.